National Institutes of Health

Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages research grant applications from institutions/organizations for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA is also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. Mechanism of Support. This FOA will utilize the NIH exploratory/developmental (R21) grant mechanism and runs in parallel an FOA of identical scientific scope, PA-09-197) that encourages applications under the R01 mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Who can apply

• State governments
• Public and State controlled institutions of higher education
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV